The Chemopreventive Agent Development Research Group (CADRG) promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.
Read more About the Chemopreventive Agent Development Research Group.
News and Events
DCP/PREVENT-funded Project Presentations at the 2023 AACR Annual Meeting
Date Posted: April 28, 2023
Pre-Application Webinar: RFA-CA-23-029 Cancer Immunoprevention Network (CIP-Net)
Date Posted: April 21, 2023
Trials Test Vaccines for Prevention or Delay of Cancers Associated with Lynch Syndrome
Date Posted: February 8, 2023
NCI Funding Approved to Expand Research on Immunoprevention, Natural Products
Date Posted: January 10, 2023
TEAG Forum: NCI Drug Development Resources: PREVENT and NExT Programs
Date Posted: December 13, 2022